NCT00703911 - Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors | Biotech Hunter

Enrollment

102

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

July 31, 2010

Study Completion Date

July 31, 2010

Conditions

Congenital Bleeding DisorderHaemophilia A With InhibitorsHaemophilia B With Inhibitors

Interventions

DRUG

eptacog alfa (activated)

Treatment of patients experiencing bleeds at the discretion of the physician/caregiver

Trial Locations (16)

Novo Nordisk Investigational Site, Brussels

Novo Nordisk Investigational Site, Sandton

Novo Nordisk Investigational Site, Riyadh

Novo Nordisk Investigational Site, Prague

Novo Nordisk Investigational Site, Algiers

Novo Nordisk Investigational Site, Istanbul

Novo Nordisk Investigational Site, Mainz

Novo Nordisk Investigational Site, Paris La Défense Cedex

Novo Nordisk Investigational Site, Vienna

Novo Nordisk Investigational Site, Rome

Novo Nordisk Investigational Site, Alphen aan den Rijn

Novo Nordisk Investigational Site, Caracas

Novo Nordisk Investigational Site, Warsaw

Novo Nordisk Investigational Site, Paço de Arcos

Novo Nordisk Investigational Site, Malmo

Novo Nordisk Investigational Site, Crawley